BOSTON SCIENTIFIC CORP invested $1.5 billion in MiRus LLC for a 34% equity stake on Monday morning. The deal returns the United States firm to the balloon-expandable heart-valve market after its May 2025 exit. Investors gain exposure to the experimental SIEGEL valve, potentially worth an additional $3 billion in future acquisition payments.

Reclaiming a Stake in TAVR Technology